A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma

​ Conditions: Esophageal Squamous Cell Carcinoma (ESCC)

Interventions: Drug: Combination therapy (COMB)

Sponsors: First Affiliated Hospital of Zhejiang University

Active, not recruiting Conditions: Esophageal Squamous Cell Carcinoma (ESCC)
Interventions: Drug: Combination therapy (COMB)
Sponsors: First Affiliated Hospital of Zhejiang University
Active, not recruiting